George Mason University leads phase 2 clinical trial for pill to help maintain weight loss after GLP-1s
GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge. George Mason University is leading a new clinical trial that may help people sustain their results.
The university is one of six research sites across the U.S. administering a Phase 2 clinical trial of ARD-201, a novel weight-maintenance drug developed by Aardvark Therapeutics that works differently from existing obesity medications. Unlike injectable medications that drive ...